BALPHARMA - Bal Pharma
📢 Recent Corporate Announcements
Bal Pharma reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 19.8% YoY to ₹87.69 crore. The bottom line saw significant expansion, with net profit surging 245% YoY to ₹1.79 crore compared to ₹0.52 crore in the same quarter last year. On a sequential basis, revenue grew by 18.4% and profit more than doubled from ₹0.72 crore in Q2 FY26. The company continues to operate in a single segment, Pharmaceuticals, and maintained an unmodified audit opinion.
- Consolidated Revenue from operations increased by 19.8% YoY to ₹8,768.97 Lakhs.
- Net Profit for the quarter surged 245% YoY to ₹179.06 Lakhs from ₹51.79 Lakhs.
- Earnings Per Share (EPS) improved significantly to ₹1.12 from ₹0.33 in the year-ago period.
- Profit Before Tax (PBT) grew by 216% YoY, reaching ₹179.05 Lakhs.
- Nine-month (9M FY26) consolidated net profit stands at ₹271.63 Lakhs compared to ₹181.82 Lakhs YoY.
Bal Pharma Limited has announced the successful passage of an ordinary resolution via postal ballot for the appointment of Dr. Mukesh Beekamchand as a Non-Executive Independent Director. The appointment is for a five-year term ending February 6, 2031. Out of 6,483,843 total votes cast, 99.98% were in favor, showing strong shareholder alignment with the board's decision. This move formalizes his role following his initial appointment as an Additional Director in November 2025.
- Dr. Mukesh Beekamchand appointed as Independent Director for a 5-year term until February 2031.
- Resolution passed with 99.98% majority, representing 6,482,547 votes in favor.
- Total votes polled represented 40.72% of the total 15,920,872 equity shares.
- A total of 58 shareholders participated in the electronic voting process concluded on February 7, 2026.
Bal Pharma Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The company confirmed that all share certificates received for dematerialization during the quarter ended December 31, 2025, were processed within the 15-day prescribed time limit. The Registrar and Transfer Agent, MUFG Intime India Pvt Ltd, verified that the securities were mutilated and cancelled after due verification. This filing is a standard administrative procedure to ensure the accuracy of electronic shareholding records.
- Compliance certificate submitted for the quarter ended December 31, 2025
- Confirmation that dematerialization requests were processed within the 15-day regulatory window
- MUFG Intime India Pvt Ltd acted as the Registrar and Transfer Agent for the verification
- All physical certificates received were mutilated and cancelled as per SEBI guidelines
Bal Pharma Limited has initiated a postal ballot process to seek shareholder approval for the appointment of Dr. Mukesh Beekamchand as a Non-Executive Independent Director. The proposed appointment is for a five-year tenure ending on February 6, 2031, following his initial induction as an Additional Director on November 12, 2025. Shareholders can participate in the decision through remote e-voting, which is scheduled to take place between January 9, 2026, and February 7, 2026. The final results of the voting process are expected to be declared by February 10, 2026.
- Proposed appointment of Dr. Mukesh Beekamchand as Non-Executive Independent Director for a 5-year period.
- Remote e-voting period set from January 9, 2026 (9:00 AM) to February 7, 2026 (5:00 PM).
- Cut-off date for determining shareholder voting eligibility is January 8, 2026.
- The resolution is being proposed as an Ordinary Resolution via postal ballot through electronic means only.
- Voting results to be announced on or before February 10, 2026, and updated on the company website.
Bal Pharma Limited has informed the stock exchanges that its trading window for dealing in company securities will be closed for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of unaudited financial results for the quarter ending December 31, 2025. The window will remain closed from January 1, 2026, until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be announced separately.
- Trading window closure begins on January 1, 2026.
- Closure is related to the review of unaudited financial results for the quarter ended December 31, 2025.
- Restriction applies to all designated persons and their immediate relatives as per SEBI norms.
- The window will reopen 48 hours after the financial results are officially disclosed to the exchanges.
Financial Performance
Revenue Growth by Segment
The Formulations segment grew 30.10% YoY in Q3FY23 to INR 33.64 Cr, while the API segment contributed 50% of total revenue in FY23. Domestic formulations saw robust growth of 42.74% in Q3FY23, whereas export formulations increased by 24.41% YoY.
Geographic Revenue Split
The revenue split between Exports and Domestic markets was 66:34 in Q3FY23. The company has a global presence in 80 countries, including India, Japan, Australia, and European nations.
Profitability Margins
Operating and profitability margins improved in FY25 due to a simultaneous lowering of input chemical prices. Standalone EPS for Q3FY23 was INR 0.94, up from INR 0.82 in Q3FY22, reflecting a 14.63% improvement in per-share profitability.
EBITDA Margin
Operating margins improved in FY25 despite a moderation in revenue, primarily because the decline in input chemical prices offset the drop in API selling prices. Core profitability remains stable with a focus on enhancing returns to stakeholders.
Capital Expenditure
The company is expected to receive incentives of approximately INR 30 Cr over the next five years under the Government of India's Production Linked Incentive (PLI) scheme, which supports its manufacturing scale.
Credit Rating & Borrowing
Acuité reaffirmed a long-term rating of 'ACUITE BBB-' (Stable) and a short-term rating of 'ACUITE A3' on bank facilities totaling INR 189 Cr. Maturing debt obligations for FY25 are INR 7.49 Cr.
Operational Drivers
Raw Materials
Key raw materials include input chemicals and API intermediates, which represent a significant portion of the cost structure. Prices for these chemicals declined in FY25, aiding margin expansion.
Import Sources
China is a major source of competition and supply for Active Pharmaceutical Ingredients (APIs), significantly influencing domestic price dynamics.
Capacity Expansion
The company operates 5 manufacturing units across Bangalore, Sangli, Rudrapur, and Udaipur. It has sustained its scale through consistent demand and support from the PLI scheme.
Raw Material Costs
Raw material costs moderated in FY25 as input chemical prices fell. However, API prices also declined due to excess domestic supply and competition from China, impacting top-line revenue.
Manufacturing Efficiency
The company maintains 5 operational production units. Efficiency is supported by approvals from various international bodies including EU GMP (Malta) and WHO GMP.
Logistics & Distribution
The company distributes products to 80 countries, utilizing a fully integrated model specializing in Bulk Actives, Prescription Drugs, and Generics.
Strategic Growth
Expected Growth Rate
10.32%
Growth Strategy
Growth is driven by a strong order book of INR 71 Cr, the launch of 5 new export formulation products, and deeper market penetration in the API and Formulation segments. The company also benefits from institutional business with the Railways, Defence, and PMY-Jan Aushadhi.
Products & Services
Bulk Actives (APIs), Prescription Drugs, Generics, Pharma Intermediates, and Ayurvedic products. The portfolio includes 200 generic formulations and 22+ APIs.
Brand Portfolio
BAL Pharma, Lifezen Healthcare (Consumer Healthcare subsidiary).
New Products/Services
Recently launched 5 new products in the export formulation segment with plans to add more in subsequent quarters to enhance profitability.
Market Expansion
Targeting deeper penetration in regulated and semi-regulated markets across 80 countries, leveraging existing approvals from authorities like MCAZ Zimbabwe and TFDA Tanzania.
Strategic Alliances
Golden Drugs Private Limited was merged with Bal Pharma Limited effective March 26, 2025, to consolidate operations.
External Factors
Industry Trends
The industry is shifting toward integrated manufacturing and specialized generics. Bal Pharma is positioning itself through the PLI scheme and expansion into 20 therapeutic segments to capture this growth.
Competitive Landscape
The market is highly competitive with significant pressure from Chinese manufacturers in the bulk drug segment.
Competitive Moat
The moat is built on a 35-year operational track record and a wide array of international regulatory approvals, which are difficult and time-consuming for competitors to replicate.
Macro Economic Sensitivity
The company is sensitive to global pharmaceutical pricing trends and government regulations, which highly intervene in the industry.
Consumer Behavior
Increased demand for affordable generics through government schemes like Jan Aushadhi is driving domestic formulation volumes.
Geopolitical Risks
Trade dynamics with China significantly affect API pricing and domestic supply levels, impacting the company's competitive positioning.
Regulatory & Governance
Industry Regulations
Operations must comply with WHO GMP, EU GMP (Malta), and various national health authorities (NAFDAC Nigeria, FDA Philippines, etc.). Prohibitions by these bodies can significantly affect operations.
Legal Contingencies
The company received an unmodified opinion from auditors for its FY25 results, indicating no major disclosed legal or financial reporting discrepancies.
Risk Analysis
Key Uncertainties
Fluctuations in API prices and the intensive nature of working capital operations are the primary business uncertainties.
Geographic Concentration Risk
66% of revenue is derived from exports, providing geographic diversification across 80 countries, though it increases exposure to global regulatory shifts.
Third Party Dependencies
Moderate dependency on Chinese suppliers for certain chemical intermediates and competition in the API market.
Technology Obsolescence Risk
The company invests in R&D through Bal Research Foundation to mitigate the risk of product obsolescence in the generic market.
Credit & Counterparty Risk
The company maintains an adequate liquidity position with Net Cash Accruals of INR 17.01 Cr, providing a buffer against counterparty credit risks.